Silence Therapeutics plc 8K

Silence Therapeutics plc reported positive topline Phase 2 SANRECO results for divesiran in polycythemia vera, meeting the primary endpoint and supporting advancement into Phase 3 in 2027.

On August 10, 2026, Silence Therapeutics plc released an investor presentation furnishing topline Phase 2 SANRECO trial results for its siRNA candidate divesiran in polycythemia vera, reporting that the study met its primary endpoint with 88% of divesiran-treated, phlebotomy-dependent PV patients maintaining hematocrit below 45% without phlebotomies between weeks 18 and 36 versus 19% on placebo, alongside marked reductions in phlebotomy rates, improvements in hematologic and symptom measures, and a generally well-tolerated safety profile, and outlining plans to present full results at the ASH Congress, hold an end-of-Phase 2 meeting by year-end, and initiate a Phase 3 trial in the first half of 2027.

Filing Facts

CIK

1479615

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-341293

Alert Tier

6